Tandem Capital Management Corp ADV Boosts Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Tandem Capital Management Corp ADV boosted its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 2.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 38,851 shares of the life sciences company’s stock after acquiring an additional 1,058 shares during the period. Tandem Capital Management Corp ADV’s holdings in Integra LifeSciences were worth $1,692,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in IART. Vanguard Group Inc. raised its holdings in shares of Integra LifeSciences by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock valued at $273,435,000 after buying an additional 72,294 shares during the period. Cooke & Bieler LP increased its stake in Integra LifeSciences by 4.4% during the 4th quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock worth $123,447,000 after buying an additional 120,410 shares during the period. Victory Capital Management Inc. boosted its position in Integra LifeSciences by 19.5% in the 3rd quarter. Victory Capital Management Inc. now owns 1,465,115 shares of the life sciences company’s stock valued at $55,953,000 after buying an additional 238,816 shares during the period. Deerfield Management Company L.P. Series C acquired a new position in shares of Integra LifeSciences in the third quarter worth $43,034,000. Finally, Assenagon Asset Management S.A. acquired a new position in shares of Integra LifeSciences in the third quarter worth $25,443,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IART has been the topic of a number of research analyst reports. Truist Financial cut their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a report on Friday, March 1st. StockNews.com downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. JMP Securities dropped their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research report on Thursday, February 29th. Finally, Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price on the stock in a report on Wednesday, April 3rd. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $44.89.

Integra LifeSciences Trading Down 3.3 %

Shares of IART stock traded down $0.97 during trading hours on Thursday, reaching $28.41. 1,581,135 shares of the stock traded hands, compared to its average volume of 705,624. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $2.23 billion, a PE ratio of 34.23, a PEG ratio of 0.88 and a beta of 1.12. Integra LifeSciences Holdings Co. has a 1-year low of $27.18 and a 1-year high of $56.41. The business has a fifty day moving average price of $35.67 and a 200 day moving average price of $38.83.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). The business had revenue of $397.00 million for the quarter, compared to analysts’ expectations of $399.30 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The company’s revenue was down .3% compared to the same quarter last year. During the same period last year, the firm earned $0.94 EPS. On average, equities research analysts forecast that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.